Compare Pinterest Inc (PINS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Summit Therapeutics Inc — how do they compare? Pinterest Inc trades at $22.54 (market cap $12.79B), while Summit Therapeutics Inc trades at $14.75 (market cap $11.34B). The key difference: Pinterest Inc and Summit Therapeutics Inc are close in size by market cap, and Pinterest Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| PINS | SMMT | |
|---|---|---|
Market Cap | $12.79B | $11.34B |
Sector | Media | Health |
52-Week High | $39.17 | $29.32 |
52-Week Low | $15.42 | $13.05 |
Enterprise Value | $12.69B | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $22.835, down 1.57% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $27.53. Revenue grew to $4.22B in 2025, with net income turning positive at $416.86M, though Q2 2026 earnings are pending. Recent news highlights focus on user growth and e-commerce integration, while insider sales and cash flow trends warrant monitoring.
The stock presents upside potential from strong analyst buy ratings and revenue expansion, but risks include negative net cash flow, high valuation multiples, and competitive pressures in social media. Investor sentiment is cautiously optimistic ahead of Q2 earnings, with institutional activity showing mixed signals.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
